دورية أكاديمية
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience.
| العنوان: | Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience. |
|---|---|
| المؤلفون: | Ma R; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Zhu DP; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Zhang XH; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Xu LP; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Wang Y; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Mo XD; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Lv M; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Zhang YY; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Cheng YF; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Yan CH; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Chen YH; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Chen Y; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Wang JZ; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Wang FR; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Han TT; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Kong J; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Wang ZD; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Han W; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Chen H; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Chang YJ; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., He Y; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Xu ZL; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Zheng FM; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Fu HX; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Liu KY; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Huang XJ; Peking University People's Hospital, Beijing, China.; Peking University Institute of Hematology, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Sun YQ; Peking University People's Hospital, Beijing, China. sunyuqian83@hotmail.com.; Peking University Institute of Hematology, Beijing, China. sunyuqian83@hotmail.com.; National Clinical Research Center for Hematologic Disease, Beijing, China. sunyuqian83@hotmail.com.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China. sunyuqian83@hotmail.com. |
| المصدر: | Bone marrow transplantation [Bone Marrow Transplant] 2024 Jul; Vol. 59 (7), pp. 991-996. Date of Electronic Publication: 2024 Apr 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: London : Nature Publishing Group Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986- |
| مواضيع طبية MeSH: | Salvage Therapy*/methods , Transplantation, Haploidentical*/methods, Humans ; Adult ; Male ; Female ; Middle Aged ; Adolescent ; Hematopoietic Stem Cell Transplantation/methods ; Transplantation Conditioning/methods ; Graft Rejection/etiology ; Young Adult ; Transplantation, Homologous/methods |
| مستخلص: | Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. However, there are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). Herein, we report updated outcomes in 30 patients using this method. The median time of the second transplantation was 96.5 (33-215) days after the first transplantation. Except for one patient who died at +19d and before engraftment, neutrophil engraftments were achieved in all patients at 11 (8-24) days, while platelet engraftments were achieved in 22 (75.8%) patients at 17.5 (9-140) days. The 1-year OS and DFS were 60% and 53.3%, and CIR and TRM was 6.7% and 33.3%, respectively. Compared with the historical group, neutrophil engraftment (100% versus 58.5%, p < 0.001) and platelet engraftment (75.8% versus 32.3%, p < 0.001) were better in the novel regimen group, and OS was also improved (60.0% versus 26.4%, p = 0.011). In conclusion, salvage haploidentical transplantation from a different donor using the novel regimen represents a promising option to rescue patients with graft failure after the first haploidentical transplantation. (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.) |
| References: | Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:642–9. (PMID: 10.1016/j.jtct.2021.04.00734304802) Ozdemir ZN, Civriz Bozdag S. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57:163–7. (PMID: 10.1016/j.transci.2018.04.01429724627) Alcazer V, Peffault de Latour R, Ader F, Labussiere-Wallet H. Graft failure after allogeneic hematopoietic stem cell transplantation: definition and risk factors. Bull Cancer. 2019;106:574–83. (PMID: 10.1016/j.bulcan.2019.03.00931060736) Mattsson J, Ringden O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:165–70. (PMID: 10.1016/j.bbmt.2007.10.025181622382344125) Ferra C, Sanz J, Diaz-Perez MA, Morgades M, Gayoso J, Cabrera JR, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56:656–62. (PMID: 10.3109/10428194.2014.93084924913510) Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother. 2014;15:23–36. (PMID: 10.1517/14656566.2014.85253724156789) Nagler A, Labopin M, Swoboda R, Kulagin A, Velardi A, Sanz J, et al. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2023;58:1008–16. (PMID: 10.1038/s41409-023-02012-5) Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, et al. Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014;8912:1097–101. (PMID: 10.1002/ajh.23845) Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008;14:859–66. (PMID: 10.1016/j.bbmt.2008.05.005186405684548938) Sun Y, Xu L, Liu D, Zhang X, Wang Y, Han W, et al. Second transplantation for 22 patients with graft failure after first allogeneic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2014;35:673–7. (PMID: 25152110) Chen J, Pang A, Zhao Y, Liu L, Ma R, Wei J, et al. Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology. 2022;271:293–9. (PMID: 10.1080/16078454.2022.2042064) Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29:1754–62. (PMID: 10.1038/leu.2015.75257720274527886) Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119:978–85. (PMID: 10.1002/cncr.2776123097265) Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54. (PMID: 10.1200/JCO.2005.09.11715753458) Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50. (PMID: 10.1016/j.bbmt.2008.03.005184899892633246) Giammarco S, Raiola AM, Di Grazia C, Bregante S, Gualandi F, Varaldo R, et al. Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transpl. 2021;56:1291–6. (PMID: 10.1038/s41409-020-01183-9) Harada K, Najima Y, Kato M, Fuji S, Shinohara A, Nakamae H, et al. Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;116:744–53. (PMID: 10.1007/s12185-022-03405-w35767142) Prata PH, Resche-Rigon M, Blaise D, Socie G, Rohrlich PS, Milpied N, et al. Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:1798–802. (PMID: 10.1016/j.bbmt.2019.05.01331129355) Sun YQ, Wang Y, Wang FR, Yan CH, Cheng YF, Chen YH, et al. Graft failure in patients with hematological malignancies: a successful salvage with a second transplantation from a different haploidentical donor. Front Med. 2021;8:604085. (PMID: 10.3389/fmed.2021.604085) Konuma T, Harada K, Kondo T, Masuko M, Uchida N, Yano S, et al. Salvage single-unit unrelated cord blood transplantation for graft failure following initial allogeneic transplantation in adult acute myeloid leukemia: trends in outcomes over the past 20 years. Bone Marrow Transpl. 2022;57:1848–50. (PMID: 10.1038/s41409-022-01840-1) Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, et al. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2020;55:1784–95. (PMID: 10.1038/s41409-020-0821-9) Wegener D, Lang P, Paulsen F, Weidner N, Zips D, Ebinger M, et al. Immunosuppressive total nodal irradiation-based reconditioning regimens after graft rejection or graft failure in pediatric patients treated with myeloablative allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2019;104:137–43. (PMID: 10.1016/j.ijrobp.2018.12.03130593907) Kliman D, Bilmon I, Kwan J, Blyth E, Micklethwaite K, Panicker S, et al. Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single-centre case series. Intern Med J. 2018;48:988–91. (PMID: 10.1111/imj.1397930133987) Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111:292–302. (PMID: 10.1111/j.1365-2141.2000.02306.x11091216) Teltschik HM, Heinzelmann F, Gruhn B, Feuchtinger T, Schlegel P, Schumm M, et al. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 2016;175:115–22. (PMID: 10.1111/bjh.14190273411805132112) Huang XJ. Overcoming graft failure after haploidentical transplantation: is this a possibility? Best Pract Res Clin Haematol. 2021;34:101255. (PMID: 10.1016/j.beha.2021.10125533762109) Prabahran A, Koldej R, Chee L, Ritchie D. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv. 2022;6:1947–59. (PMID: 10.1182/bloodadvances.2021004537344926858941468) |
| تواريخ الأحداث: | Date Created: 20240402 Date Completed: 20240705 Latest Revision: 20240705 |
| رمز التحديث: | 20240706 |
| DOI: | 10.1038/s41409-024-02276-5 |
| PMID: | 38565964 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-5365 |
|---|---|
| DOI: | 10.1038/s41409-024-02276-5 |